Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439240 · ClinicalTrials.gov registry record · Phase 2
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT04439240: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT04439240 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04439240, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This phase II MATCH treatment trial identifies the effects of AZD4547 in patients whose cancer has genetic changes called FGFR gene alterations. AZD4547 may stop the growth of cancer cells by blocking FGFR proteins which may be needed for cell growth. Researchers hope to learn if AZD4547 will shrink this type of cancer or stop its growth.
Interventions
- DRUG FGFR Inhibitor AZD4547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2016-05-31 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04439240
The ClinicalTrials.gov registry entry for NCT04439240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FGFR Inhibitor AZD4547 is the first listed.
NCT04439240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04439240 about?
NCT04439240 is a clinical study titled "Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)". This phase II MATCH treatment trial identifies the effects of AZD4547 in patients whose cancer has genetic changes called FGFR gene alterations. AZD4547 may stop the growth of cancer cells by blocking FGFR proteins which may be needed for cell growth. Researchers hope to learn if AZD4547 will shrink...
What is the current status of trial NCT04439240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2016-05-31. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT04439240?
The interventions under investigation include: FGFR Inhibitor AZD4547 (DRUG).
Who is sponsoring clinical trial NCT04439240?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.